

Review

Specialized Pro-Resolving Mediators from Omega-3 Fatty Acids Improve Amyloid- β Phagocytosis and Regulate Inflammation in Patients with Minor Cognitive Impairment

Milan Fiala^{a,*}, Niccolo Terrando^b and Jesmond Dalli^c

^aDepartment of Surgery, UCLA School of Medicine, Los Angeles, California, USA

^bDepartments of Anesthesiology, Basic Science Division, Duke University Medical Center, Durham, North Carolina, USA

^cCenter for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA

Accepted 6 June 2015

Abstract. In this review we discuss the immunopathology of Alzheimer's disease (AD) and recent advances in the prevention of minor cognitive impairment (MCI) by nutritional supplementation with omega-3 fatty acids. Defective phagocytosis of amyloid- β (A β) and abnormal inflammatory activation of peripheral blood mononuclear cells (PBMCs) are the two key immune pathologies of MCI and AD patients. The phagocytosis of A β by PBMCs of MCI and AD patients is universally defective and the inflammatory gene transcription is heterogeneously deregulated in comparison to normal subjects. Recent studies have discovered a cornucopia of beneficial anti-inflammatory and pro-resolving effects of the specialized proresolving mediators (SPMs) resolvins, protectins, maresins, and their metabolic precursors. Resolvin D1 and other mediators switch macrophages from an inflammatory to a tissue protective/pro-resolving phenotype and increase phagocytosis of A β . In a recent study of AD and MCI patients, nutritional supplementation by omega-3 fatty acids individually increased resolvin D1, improved A β phagocytosis, and regulated inflammatory genes toward a physiological state, but only in MCI patients. Our studies are beginning to dissect positive factors (adherence to Mediterranean diet with omega-3 and exercise) and negative factors (high fat diet, infections, cancer, and surgeries) in each patient. The *in vitro* and *in vivo* effects of omega-3 fatty acids and SPMs suggest that defective phagocytosis and chronic inflammation are related to defective production and/or defective signaling by SPMs in immune cells.

Keywords: Amyloid- β , fatty acids, inflammation, mild cognitive impairment, omega-3

INTRODUCTION

Phagocytosis of amyloid- β (A β) and inflammation are the two faces of innate immunity underlying much of the Alzheimer's disease (AD) immunopathology

and are an excellent target for AD prevention. Curcuminoids, vitamin D3, and omega-3 fatty acids are popular preventive supplements that have been shown to enhance phagocytosis and tame inflammation [1]. Here we review the pathology of the innate immune system in AD patients and the advances in the prevention of mild cognitive impairment (MCI) by the lipidic mediators termed specialized proresolving mediators (SPMs) that are derived from omega-3 fatty acids [2].

*Correspondence to: Milan Fiala, MD, Department of Surgery, UCLA School of Medicine, Suite 220, UCLA Medical Plaza, Los Angeles, CA 90095-7022, USA. Tel./Fax: +3102066392; E-mail: Fiala@mednet.ucla.edu.

The strategy we employed in our *in vitro* studies is based on investigating the clearance of $A\beta_{1-42}$ by immune and endothelial cells in the brain tissues of AD patients and using omega-3 fatty acids and SPMs as agonists in macrophages. The *in vivo* aim of this approach is to rectify the defective clearance of $A\beta_{1-42}$ by the monocyte/macrophages of AD patients using supplementation with omega-3 fatty acids and increasing SPMs [3–5]. Omega-3 fatty acids are an important component of the Mediterranean diet, which is high in fish and olive oil, low in meat, and moderate in dairy products [6]. Omega-3 fatty acids are precursors of anti-inflammatory and pro-resolving mediators that improve the immune clearance of $A\beta_{1-42}$ (see below “Role of SPMs in dementia and Alzheimer’s disease”).

AMYLOID- β_{1-42} NEUROTOXICITY

Neuronal damage in the AD brain is related to accumulation of $A\beta_{1-42}$ and phospho-tau [7] as well as the inflammation induced by these proteins. Apolipoprotein E $\epsilon 4$ allele genotype is a risk factor for accumulation of $A\beta_{1-42}$ in the brain related to increased amyloidogenic β - and γ -cleavage of amyloid- β protein precursor ($A\beta$ PP), and loss of sirtuin T1, and reduced clearance across the blood-brain barrier. The products of β - and γ -cleavage of $A\beta$ PP are the peptides s $A\beta$ PP β , $A\beta_{1-42}$, Jcasp, and C31, which cause neurite retraction and cell death [8]. The mechanisms of $A\beta_{1-42}$ neurotoxicity [9] involve inflammatory activation, prion-like toxicity, and production of neurofibrillary tangles. Upstream of $A\beta_{1-42}$, neurotoxicity is attributed to prostaglandins, and additionally to F2-isoprostanes produced by free radical-catalyzed peroxidation of arachidonic acid [10]. In addition, possible culprits in neural damage, especially in APOE $\epsilon 4$ carriers, are the products of oxidative stress, 4-hydroxy-2-nonenal, which is generated by peroxidation of the ω -6 polyunsaturated fatty acid (PUFA) arachidonic acid, and 4-hydroxy-2-hexenal, which is produced by peroxidation of the ω -3 PUFAs docosahexaenoic acid (DHA) [11].

AMYLOID- β_{1-42} CLEARANCE IN MODEL SYSTEMS

Enhancement of $A\beta_{1-42}$ clearance from the brain has a high priority in therapeutic research. $A\beta_{1-42}$ clearance across the blood-brain barrier and choroid plexus in rodent model systems is reduced by APOE $\epsilon 4$ due

to redirection of $A\beta_{1-42}$ from the low-density lipoprotein receptor-related protein 1 to the very low-density lipoprotein receptor [12–14]. A defect of systemic $A\beta_{1-42}$ elimination by liver and kidney pathologies promotes $A\beta_{1-42}$ accumulation [15]. Bexarotene stimulation of the peroxisome proliferator-activated nuclear receptor γ (PPAR γ) and liver X receptor, in coordination with the retinoid X receptor, in the $A\beta$ PP/PS1 model increased memory and $A\beta_{1-42}$ clearance and degradation [16]. Subsequent experience in other laboratories with bexarotene only partially validated these results [17]. The PPAR γ agonist pioglitazone increased $A\beta_{1-42}$ clearance in a mouse model and polarized microglia to pro-resolution M2 type [18]. In a mouse model, $A\beta_{1-42}$ phagocytosis was enhanced by inhibition of the EP2 receptor for prostaglandin E and also by CD36 upregulation [19]. $A\beta_{1-42}$ is degraded by enzymes present in the brain but reduced in APOE $\epsilon 4$ carriers, i.e., neprilysin and insulin-degrading enzyme [20, 21].

These strategies have not been translated into therapeutics for a number of reasons, including the following: mouse inflammatory responses show low correlation with human responses [22]; neurotoxicity of $A\beta$ differs in mice and men [23]; and mice do not have the genetic variability in the HLA complex genes and Toll-like receptors observed in patients [24].

IMMUNE CLEARANCE IN HUMAN BRAIN AND RECEPTORS FOR $A\beta_{1-42}$ ON IMMUNE CELLS

In patients with sporadic AD, $A\beta_{1-42}$ accumulation is related to decreased clearance, but not to increased production [25]. One cogent reason for decreased $A\beta_{1-42}$ clearance is the reduction of immune clearance by AD macrophages, which display reduced phagocytosis and degradation in comparison to normal macrophages [3]. Although soluble $A\beta_{1-42}$ is transported across the brain endothelia, $A\beta_{1-42}$ aggregates in the brain and its clearance then depends upon degradation and transport by immune cells. In animal models, $A\beta_{1-42}$ phagocytosis and degradation are attributed to brain microglia recruited from the bone marrow and the blood by chemokines, such as CCL2 [26]. In the AD brain, macrophage-like cells are observed on immunohistochemical examination to traverse from the microvessels into the neuropil, as documented in HIV-1 encephalitis [27, 28] and the AD brain [3]. Macrophages are also believed to phagocytize and degrade extracellular tau [29].

Both microglia and macrophages belong to the innate immune system and have similar receptors for $A\beta_{1-42}$: (a) the scavenger receptors including class A (SCARA-1 and MARCO), class B (SCARB-1 and CD36), and other (CD68), (b) the receptor for advanced glycation end product (RAGE) called CD163; (c) the G-protein coupled receptors (GPCRs) lipoxin A_4 /formyl peptide receptor 2 (ALX/FPR2) and chemokine-like receptor 1 (CMKLR1); and (d) the toll-like receptors (TLRs) [30, 31]. In addition, the studies of non-steroidal anti-inflammatory drugs targeting prostaglandins have spurred interest in the modulation of prostanoid receptors [32]. Recently an increased risk of AD was found to be related to heterozygous variants in the triggering receptor expressed on myeloid cells 2 protein (TREM2) [33]. TREM2 is expressed on alternatively activated M2 macrophages and attenuates macrophage activation [34].

GPCRs are the most interesting from the omega-3 therapeutic viewpoint as the ALX/FPR2 antagonist blocked $A\beta_{1-42}$ -induced IL-1 β in monocytes [35] and ALX/FPR2 antibody blocked enhancement of $A\beta_{1-42}$ phagocytosis by resolvin D1 [36]. CMKLR1 is a receptor for another lipid mediator resolvin E1 [37]. Thus GPCR signaling may be crucial for the balance between inflammation and phagocytosis. The roles of $A\beta$ receptors are summarized in an excellent review of animal studies [38]: a) CD14 functions in the recognition and binding of $A\beta$ for its internalization and clearance from the brain parenchyma [31, 39]; b) RAGE has a role in the induction of inflammatory cascade; c) TREM has a role in clearance of $A\beta$; and d) complement and Fc receptors, ALX/FPR2, CD36, and TLRs are important in both inflammation and phagocytosis. The multiplicity and heterogeneity of these receptors reduces therapeutic potential of the receptor blockade. The use of endogenous SPMs discussed below may provide a physiological approach to optimize the balance between effective phagocytosis and moderate inflammation.

IMMUNE PATHOLOGIES IN AD PATIENTS

Peripheral blood mononuclear cells (PBMCs) of AD patients display specific immune pathologies. Defective phagocytosis of $A\beta_{1-42}$ by immune cells of AD patients was first noted with AD macrophages [40]. In subsequent studies, almost all AD patients have been found defective in $A\beta_{1-42}$ phagocytosis in macrophages and monocytes, and deregulated with respect to inflammatory activation of PBMCs.

The defect in phagocytosis was found to be specific for genuine $A\beta_{1-42}$, as scrambled $A\beta_{1-42}$ was not phagocytized, whereas *E. coli* was phagocytized by both normal and AD macrophages [41]. In a “tissue assay” with sections of the AD brain incubated with macrophages, strikingly different results were observed with normal macrophages phagocytizing and clearing $A\beta_{1-42}$ compared to AD macrophages aggregating and becoming apoptotic after up loading $A\beta_{1-42}$ in the AD brain tissue [3]. Fibrillar $A\beta_{1-42}$ was cleared by normal macrophages but caused apoptosis of AD macrophages. These defects may explain the apoptosis of macrophages around brain microvessels and release of $A\beta_{1-42}$ in the wall of congophilic brain vessels [42].

ENHANCEMENT OF IMMUNE CLEARANCE OF $A\beta_{1-42}$ IN THE AD BRAIN

In the AD brain, $A\beta$ plaques are cleared by macrophages, which appear distinct from ramified microglia [28]. According to a confocal microscopic study of the AD brain in a “tissue assay” (monocytes are co incubated with the AD brain tissue slices), monocyte/macrophages intrude into neurons and upload $A\beta$ [42]. Thus monocyte/macrophages, depending on their fitness, may upload and clear $A\beta_{1-42}$ from both the plaques and neurons.

Epidemiological studies of dementia in various populations have produced strong rationale for AD prevention using natural substances based on local customs [16, 17, 19]. Fortuitously, these substances have been shown to increase $A\beta_{1-42}$ phagocytosis [1]. The nutrients believed to be related to better cognition according to population studies include omega-3 fatty acids, vitamin D3, curcumin, and other natural substances [1]. Using these substances *in vitro*, $A\beta_{1-42}$ phagocytosis by monocytes and macrophages was modulated by vitamin D3, curcumin, and, in particular, by the omega-3 fatty acids DHA and eicosapentaenoic acid [36]. Administration of omega-3 fatty acids to patients with dementia in a randomized, double-blind, placebo-controlled clinical trial significantly slowed the decline of Mini-Mental State Examination (MMSE) scores in a subgroup of MCI patients with MMSE >27 points [43]. A recent study of supplementation by omega-3 fatty acids, antioxidants, and resveratrol in the drink Smartfish (Smartfish Inc., Oslo, Norway) showed that MCI patients on this supplement maintained their cognition with initial MMSE 25.9 and final MMSE 25.7 after 4–17 months [5].

OMEGA-3 FATTY ACID ANTI-INFLAMMATORY AND PRO-RESOLVING MECHANISMS

The roles of prostaglandin E₂ in inflammation, thromboxanes in platelet aggregation and constriction of vascular smooth muscle, and leukotrienes in asthma were gleaned in the laboratory of Samuelson [44] in the 1960s and 1970s [44]. The anti-inflammatory and pro-resolving lipoxins derived from arachidonic acids were discovered in 1980s at Karolinska Institute, and the first resolvins in Serhan's laboratory in 2000 [45]. The concept of active resolution of inflammation became apparent in inflammatory exudates when the lipid mediator class switched from pro-inflammatory prostaglandins and leukotrienes to anti-inflammatory and pro-resolving lipoxins [45, 46]. Therefore, this class switch process leads to a shift in the exudate lipid mediator profile from one that is pro-inflammatory during the initial pro-inflammatory response to an anti-inflammatory and pro-resolving with elevated SPMs [47].

The molecular basis of the omega-3 actions in the central nervous system was discovered in Serhan's [48] and Bazan's laboratories [49]. These researchers observed the production of 10*R*,17*S*-docosatriene called neuroprotectin D1 (NPD1; 10*R*,17*S*-dihydroxy-4*Z*,7*Z*,11*E*,13*E*,15*Z*,19*Z*-docosahexaenoic acid) in oxidative stress-challenged human retinal pigment epithelial cells [50] and the rat brain undergoing ischemia-reperfusion [49]. Interestingly, IL-1 β enhances the production of NPD1 which in turn inhibits IL-1 β -stimulated production of COX-2 and caspase-3 activation [51], suggesting that during inflammation the SPMs production is tightly regulated to achieve optimal phagocytosis and neuroprotection.

STIMULATION OF INFLAMMATION BY PROSTAGLANDINS AND LEUKOTRIENES AND TERMINATION OF ACUTE INFLAMMATION BY SPECIALIZED PRO-RESOLVING MEDIATORS

Inflammation is induced by the pro-inflammatory leukotrienes LTB₄ (potent leukocyte chemattractant), LTC₄, LTD₄, LTE₄ (vascular leakage, smooth muscle contraction), and the prostaglandins E₂ and D₂ (PGE₂ and PGD₂), and cytokines that stimulate vascular leakage and promote neutrophil diapedesis in the early phase of inflammation. LTB₄ stimulates inflammation by binding to the G-protein coupled receptors (GPCRs)

BLT1 and BLT2 that are present in the membranes of the relevant cell types and triggers the expression of chemokines and cytokines (IL-6 and IL-8). After the early phase, PGE₂ and PGD₂ switch production of lipid mediators to SPMs via the upregulation of the key biosynthetic enzyme 15-lipoxygenase (15-LO) type 1 in leukocytes [52]. This promotes the conversion of (a) arachidonic acid to lipoxin A₄ (LXA₄) and LXB₄, and (b) the omega-3 PUFA DHA to the D-series resolvins and protectins/neuroprotectins [52]. The mediators are produced in humans by 15-LO and 5-lipoxygenase that convert the PUFA substrate via subsequent lipoxygenation reactions [52]. For recent detailed reviews on the biosynthetic pathways, interested readers are directed to the reviews [53, 54]. Specific members of these new families of mediators from the DHA metabolome are named D-series resolvins (Resolvin D1 to Resolvin D6), protectins (including protectin D1-neuroprotectin D1), and maresins (MaR1 and MaR2) [53].

Resolution of inflammation involves limiting of neutrophil recruitment, promotion of nonphlogistic recruitment, and activation of monocytes, and non-phlogistic phagocytosis and lymphatic clearance of apoptotic neutrophils by macrophages [55]. Alternatively, chronic inflammation can result from excessive and/or unresolved inflammatory responses. Resolution of inflammation is mediated by SPMs, each with a specialized function. LXA₄ inhibits leukocyte trafficking *in vivo* by activating the lipoxin A₄ receptor (denoted ALX/FPR2). Resolvin E1 directly activates CMKLR1/ERV1 on mononuclear cells and dendritic cells and acts as a competitive antagonist at the leukotriene B₄ receptor (denoted BLT). Resolvin D1 binds to ALX/FPR2 and another G protein coupled receptor called GPR 32, and inhibits neutrophil migration and promotes their phagocytosis by macrophages [56]. Aspirin-triggered resolvin D1 (AT-RvD1) inhibits the release of IL-6 and protects the brain after surgical injury from neuroinflammation, synaptic dysfunction, and cognitive decline [57]. DHA is also converted by macrophages via 14-lipoxygenation to the Maresins (*macrophage mediators in resolving inflammation*). The first member of this family identified was Maresin 1 (MaR1; 7*R*,14*S*-dihydroxy-docosa-4*Z*,8*E*,10*E*,12*Z*,16*Z*,19*Z*-hexaenoic acid). These mediators potentially stimulate macrophage phagocytosis of apoptotic cells in a stereospecific manner. They also regulate both inflammation and chemotherapy induced pain by inhibiting TRPV1 currents in neurons and limits neutrophil recruitment [58]. Recently, a novel family of macrophage- derived pro-resolving

mediators coined Maresins Conjugates in Tissue Regeneration (MCTR) was identified. These novel resolution agonists carry potent organ-protective, tissue-regenerative, and pro-resolving actions [59]. The production of proresolving mediators is evolutionarily conserved being identified in a number of species from planaria, to mice, baboons and humans [60, 61]. Whereas in planaria RvE1, MaR1, MCTR1 and MCTR2 accelerate tissue regeneration, in mice and humans, this process is regulated by select macrophage subtypes [62].

ROLE OF MACROPHAGES IN RESOLUTION OF INFLAMMATION

Macrophages are key players in various host protective processes ranging from protection against pathogen infections to clearance of cellular debris and tissue repair and regeneration, with different macrophage subsets being associated with the propagation or resolution of inflammation [63, 64]. Classically M1 macrophages are regarded as pro-inflammatory, whereas macrophages displaying the M2 phenotype are anti-inflammatory/pro-resolving. Recent evidence demonstrates that macrophage phenotypes *in vivo* display intermediate characteristics to these extreme descriptions giving rise to more physiologically relevant phenotypes, such as those described by Stables and colleagues [65] and Schiff-Zuick and colleagues [66]. A number of studies have now investigated the actions of pro-resolving mediators on regulating the macrophage phenotype switch. Resolvin D1 promotes the adipose macrophage phenotype switch toward an M2-like phenotype in a mouse model of diet induced obesity [67], and in obese-diabetic mice in hepatic macrophages during a model of insulin resistance and non-alcoholic steatohepatitis [68]. Resolvin D1 decreases the expression of anti-coactivator-associated arginine methyltransferase 1 (CARM1), as well as downstream genes including colony-stimulating factor 3, intercellular adhesion molecule 1, and monocyte inflammatory protein 2 in resolution phase peritoneal macrophages. This ability to switch macrophages from an inflammatory to a tissue protective/pro-resolving phenotype was also found with other pro-resolving mediators, including the maresin conjugates in tissue regeneration (MCTR1 and MCTR2) [59], maresin 1, as well as the maresin biosynthetic intermediate 13S, 14S-epoxy-MaR (13S,14S-epoxy-4Z,7Z,9E,11E,16Z,19Z- docosahexaenoic acid [69].

HETEROGENEITY OF INFLAMMATION IN AD PATIENTS

It is important to realize that the results of therapeutic trials will not be uniform due to the heterogeneity of MCI patients. In our study of AD patients, we distinguished two subgroups: Type I (non-inflammatory) and Type II (inflammatory), but even in the inflammatory group, the upregulated cytokines and chemokines and the responses to anti-inflammatory therapy by omega-3 differed between patients (see next paragraph). Another example of the heterogeneity is found in the study of β -secretase inhibitors, which failed to achieve overall significance but observed an effect in an MCI subgroup [70]. Thus anti-inflammatory and other therapeutic approaches in MCI and AD patients need to be personalized.

ROLE OF SPMS IN DEMENTIA AND ALZHEIMER'S DISEASE

SPMs are investigated in AD on the basis of their anti-apoptotic effects, down regulation of inflammation in neural cells, shift to non-amyloidogenic processing of A β PP, and activation of PPAR signaling. A protective role of the neuroprotectin D1 (NPD1) in the AD brain has been suspected due to its decreased level and a decreased expression of phospholipase A₂ and 15-LOX type 1 in the hippocampal cornu ammonis region 1 [71]. Furthermore, in a mouse model of surgery-induced cognitive decline, aspirin-triggered resolvin D1 prevented surgery-induced neuronal dysfunction by modulating astrocyte activity and synaptic plasticity in the hippocampus, thus ameliorating cognitive loss [57]. Surgery and anesthesia have also been implicated in the progression of AD pathology, suggesting a possible role for inflammation and oxidative stress damage in modulating A β accumulation and tau phosphorylation [72, 73]. However, not all anesthetic agents have been shown to exacerbate AD pathology [74]; some may exert even neuroprotective actions, including jumpstarting endogenous resolution and providing anti/inflammatory actions [75]).

Omega-3 fatty acids are popular supplements taken by many people for prevention of health problems including dementia. Studies in healthy volunteers showed a significant increase in RvE1, 18R/S-HEPE, 17R/S-HDHA, and 14R/S-HDHA, but not other SPMs, after short-term omega-3 supplementation [76, 77]. In another study, plasma concentrations of all SPMs were increased after a single administration of omega-3

capsule and aspirin [60]. We have evaluated immunosupportive and pro- and anti-inflammatory effects of nutritional supplementation in MCI patients by the Smartfish drink (Smartfish, Oslo, Norway) containing omega-3, natural anti-oxidants, resveratrol and vitamin D3. After a 4- to 17-month supplementation, the phagocytosis of A β by monocytes was significantly increased and the pro-resolving mediator RvD1 increased in the macrophages of 80% of the MCI patients [5].

The brain damage in AD has been ascribed to inflammatory cytokines, in particular IL-6, TNF- α , IL-1 β , and TGF- β [78]. However, the transcriptome of AD patients' PBMCs is either "inflammatory" (with increased *TLRs*, *IL-1*, *IL1R1*, and chemokines) or "non-inflammatory" (with opposite findings); however, both groups have increased *IL1RN*, *ITGB2*, and *NF κ B* [36]. Omega-3 nutritional supplementation up regulated transcription of cytokines in "non-inflammatory" patients (but not to the "inflammatory" level) and down regulated transcription in "inflammatory" patients [5, 36]. Omega-3 attenuated cognitive decline in MCI patients with MMSE >27 in a placebo-controlled study [43]. In our study, which was not placebo-controlled, the mean MMSE score was 25.9 at baseline and 25.7 after supplementation [79]. However, there are caveats in the effects of omega-3 supplementation. Previous studies [80] showed that omega-3 supplementation has less protective effect against dementia in APOE ϵ 4 carriers. In our study of 14 MCI patients, three had the APOE ϵ 4 genotype. In these patients, the improvement of A β ₁₋₄₂ phagocytosis on supplementation and the MMSE score were not sustained in two patients. The A β ₁₋₄₂ phagocytosis was generally adversely affected by intercurrent infections, surgeries, cancer, and lack of adherence to the supplementation (even for a short time). Some MCI patients did not produce RvD1 in macrophages despite immune and cognitive improvements, indicating a defect in the biosynthetic pathway for this potent pro-resolving mediator.

BLOOD BIOMARKER TEST OF A β ₁₋₄₂ PHAGOCYTOSIS

The benefits of omega-3 fatty acids are difficult to analyze in small samples by psychological tests due to the heterogeneity of their cognitive effects in individual patients. However, A β ₁₋₄₂ phagocytosis and inflammatory activation are the key pathologies in AD and MCI patients, which can be accurately measured by

flow cytometry and PCR. The flow cytometric test of fluorescent A β ₁₋₄₂ phagocytosis by monocytes had the following results: (a) A β ₁₋₄₂ uptake of <450 mean fluorescence intensity (MFI) units in AD and most MCI patients; (b) A β ₁₋₄₂ uptake of >450 MFI units in cognitively-normal subjects; (c) A β ₁₋₄₂ uptake >1000 MFI Units in cognitively-highly active University professors; (d) A β ₁₋₄₂ uptake in the AD range in some stressed caregivers and apparently cognitively normal persons not mentally and physically active [4]. Our recent results show that the test score deteriorates over time in AD and MCI patients and, contrariwise, the test is improving or is stabilized in some MCI patients who are nutritionally supplemented with the omega-3 drink Smartfish [79].

FUTURE DIRECTIONS

Omega-3-derived specialized pro-resolving mediators have strong effects on acute inflammation *in vitro* and *in vivo* and may attenuate chronic inflammation in patients with neurodegenerative diseases. Yet, large studies of omega-3 supplementation have not produced a consensus about their beneficial cognitive effects in MCI and AD patients. These difficulties can be partially overcome by nutritional supplementation of individual patients while monitoring adherence to daily therapy, A β ₁₋₄₂ phagocytosis, inflammation, and lipid mediators. Nutritional supplementation is compromised by lack of daily adherence, intercurrent infections, surgeries, cancer, endocrine and metabolic factors, and lack of a healthy and active lifestyle.

ACKNOWLEDGMENTS

J.D. was supported by NIH Grants awarded to Charles N Serhan (Grants R01GM038765 and P01GM095467). The study of omega-3 fatty acid drink was supported by Smartfish Company, Oslo, Norway in M. Fiala's laboratory.

Authors' disclosures available online (<http://j-alz.com/manuscript-disclosures/15-0367r1>).

REFERENCES

- [1] Fiala M, Weitzman R (2015) 1 α ,25 dihydroxyvitamin D3 and resolvins improve immunity to amyloid- β in patients with Alzheimer's disease. In *Diet and nutrition in dementia and cognitive decline*, Martin CR, Preedy VR, Eds. Academic Press, London, pp. 701-708.
- [2] Serhan CN, Petasis NA (2011) Resolvins and protectins in inflammation resolution. *Chem Rev* **111**, 5922-5943.

- [3] Fiala M, Liu PT, Espinosa-Jeffrey A, Rosenthal MJ, Bernard G, Ringman JM, Sayre J, Zhang L, Zaghi J, Dejbakhsh S, Chiang B, Hui J, Mahanian M, Baghaee A, Hong P, Cashman J (2007) Innate immunity and transcription of MGAT-III and Toll-like receptors in Alzheimer's disease patients are improved by bisdemethoxycurcumin. *Proc Natl Acad Sci U S A* **104**, 12849-12854.
- [4] Avagyan H, Goldenson B, Tse E, Masoumi A, Porter V, Wiedau-Pazos M, Sayre J, Ong R, Mahanian M, Koo P, Bae S, Micic M, Liu PT, Rosenthal MJ, Fiala M (2009) Immune blood biomarkers of Alzheimer disease patients. *J Neuroimmunol* **210**, 67-72.
- [5] Fiala M, Halder RC, Sagong B, Ross O, Sayre J, Porter V, Bredesen DE (2015) omega-3 Supplementation increases amyloid-beta phagocytosis and resolvin D1 in patients with minor cognitive impairment. *FASEB J* **29**, 2681-2689.
- [6] Feart C, Samieri C, Rondeau V, Amieva H, Portet F, Dartigues JF, Scarmeas N, Barberger-Gateau P (2009) Adherence to a Mediterranean diet, cognitive decline, and risk of dementia. *JAMA* **302**, 638-648.
- [7] Querfurth HW, LaFerla FM (2010) Alzheimer's disease. *N Engl J Med* **362**, 329-344.
- [8] Theendakara V, Patent A, Peters Libeu CA, Philpot B, Flores S, Descamps O, Poksny KS, Zhang Q, Cailing G, Hart M, John V, Rao RV, Bredesen DE (2013) Neuroprotective Sirtuin ratio reversed by ApoE4. *Proc Natl Acad Sci U S A* **110**, 18303-18308.
- [9] Sadigh-Eteghad S, Sabermarouf B, Majidi A, Talebi M, Farhoudi M, Mahmoudi J (2015) Amyloid-beta: a crucial factor in Alzheimer's disease. *Med Princ Pract* **24**, 1-10.
- [10] Lauretti E, Di Meco A, Chu J, Pratico D (2015) Modulation of AD neuropathology and memory impairments by the isoprostan F2alpha is mediated by the thromboxane receptor. *Neurobiol Aging* **36**, 812-820.
- [11] Montine KS, Olson SJ, Amarnath V, Whetsell WO Jr, Graham DG, Montine TJ (1997) Immunohistochemical detection of 4-hydroxy-2-nonenal adducts in Alzheimer's disease is associated with inheritance of APOE4. *Am J Pathol* **150**, 437-443.
- [12] Zlokovic BV (2013) Cerebrovascular effects of apolipoprotein E: Implications for Alzheimer disease. *JAMA Neurol* **70**, 440-444.
- [13] Castellano JM, Deane R, Gottesdiener AJ, Verghese PB, Stewart FR, West T, Paoletti AC, Kasper TR, DeMattos RB, Zlokovic BV, Holtzman DM (2012) Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Abeta clearance in a mouse model of beta-amyloidosis. *Proc Natl Acad Sci U S A* **109**, 15502-15507.
- [14] Ladu MJ, Reardon C, Van Eldik L, Fagan AM, Bu G, Holtzman D, Getz GS (2000) Lipoproteins in the central nervous system. *Ann N Y Acad Sci* **903**, 167-175.
- [15] Zolezzi JM, Bastias-Candia S, Santos MJ, Inestrosa NC (2014) Alzheimer's disease: Relevant molecular and physiopathological events affecting amyloid-beta brain balance and the putative role of PPARs. *Front Aging Neurosci* **6**, 176.
- [16] Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, Casali BT, Restivo JL, Goebel WD, James MJ, Brunden KR, Wilson DA, Landreth GE (2012) ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. *Science* **335**, 1503-1506.
- [17] Landreth GE, Cramer PE, Lakner MM, Cirrito JR, Wesson DW, Brunden KR, Wilson DA (2013) Response to comments on "ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models". *Science* **340**, 924-g.
- [18] Mandrekar-Colucci S, Karlo JC, Landreth GE (2012) Mechanisms underlying the rapid peroxisome proliferator-activated receptor-gamma-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease. *J Neurosci* **32**, 10117-10128.
- [19] Li X, Melief E, Postupna N, Montine KS, Keene CD, Montine TJ (2015) Prostaglandin E receptor subtype 2 regulation of scavenger receptor CD36 modulates microglial Abeta phagocytosis. *Am J Pathol* **185**, 230-239.
- [20] Huttenrauch M, Baches S, Gerth J, Bayer TA, Weggen S, Wirths O (2015) Neprilysin deficiency alters the neuropathological and behavioral phenotype in the 5XFAD mouse model of Alzheimer's disease. *J Alzheimers Dis* **44**, 1291-1302.
- [21] Miners JS, Baig S, Palmer J, Palmer LE, Kehoe PG, Love S (2008) Abeta-degrading enzymes in Alzheimer's disease. *Brain Pathol* **18**, 240-252.
- [22] Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, Richards DR, McDonald-Smith GP, Gao H, Hennessy L, Finnerty CC, Lopez CM, Honari S, Moore EE, Minei JP, Cuschieri J, Bankey PE, Johnson JL, Sperry J, Nathens AB, Billiar TR, West MA, Jeschke MG, Klein MB, Gamelli RL, Gibran NS, Brownstein BH, Miller-Graziano C, Calvano SE, Mason PH, Cobb JP, Rahme LG, Lowry SF, Maier RV, Moldawer LL, Herndon DN, Davis RW, Xiao W, Tompkins RG, Inflammation, Host Response to Injury, Large Scale Collaborative Research, Program (2013) Genomic responses in mouse models poorly mimic human inflammatory diseases. *Proc Natl Acad Sci U S A* **110**, 3507-3512.
- [23] Kokjohn TA, Roher AE (2009) Amyloid precursor protein transgenic mouse models and Alzheimer's disease: Understanding the paradigms, limitations, and contributions. *Alzheimers Dement* **5**, 340-347.
- [24] Netea MG, Wijmenga C, O'Neill LA (2012) Genetic variation in Toll-like receptors and disease susceptibility. *Nat Immunol* **13**, 535-542.
- [25] Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ (2010) Decreased clearance of CNS beta-amyloid in Alzheimer's disease. *Science* **330**, 1774.
- [26] Hickman SE, El Khoury J (2010) Mechanisms of mononuclear phagocyte recruitment in Alzheimer's disease. *CNS Neurol Disord Drug Targets* **9**, 168-173.
- [27] Persidsky Y, Ghorpade A, Rasmussen J, Limoges J, Liu XJ, Stins M, Fiala M, Way D, Kim KS, Witte MH, Weinand M, Carhart L, Gendelman HE (1999) Microglial and astrocyte chemokines regulate monocyte migration through the blood-brain barrier in human immunodeficiency virus-1 encephalitis. *Am J Pathol* **155**, 1599-1611.
- [28] Fiala M, Liu QN, Sayre J, Pop V, Brahmandam V, Graves MC, Vinters HV (2002) Cyclooxygenase-2-positive macrophages infiltrate the Alzheimer's disease brain and damage the blood-brain barrier. *Eur J Clin Invest* **32**, 360-371.
- [29] Majerova P, Zilkova M, Kazmerova Z, Kovac A, Paholikova K, Kovacech B, Zilka N, Novak M (2014) Microglia display modest phagocytic capacity for extracellular tau oligomers. *J Neuroinflammation* **11**, 161.
- [30] Yu Y, Ye RD (2015) Microglial abeta receptors in Alzheimer's disease. *Cell Mol Neurobiol* **35**, 71-83.
- [31] Landreth GE, Reed-Geaghan EG (2009) Toll-like receptors in Alzheimer's disease. *Curr Top Microbiol Immunol* **336**, 137-153.
- [32] Cudaback E, Jorstad NL, Yang Y, Montine TJ, Keene CD (2014) Therapeutic implications of the prostaglandin pathway in Alzheimer's disease. *Biochem Pharmacol* **88**, 565-572.

- [33] Guerreiro R, Hardy J (2013) TREM2 and neurodegenerative disease. *N Engl J Med* **369**, 1569-1570.
- [34] Turnbull IR, Gilfillan S, Cella M, Aoshi T, Miller M, Piccio L, Hernandez M, Colonna M (2006) Cutting edge: TREM-2 attenuates macrophage activation. *J Immunol* **177**, 3520-3524.
- [35] Lorton D, Kocsis JM, King L, Madden K, Brunden KR (1996) beta-Amyloid induces increased release of interleukin-1 beta from lipopolysaccharide-activated human monocytes. *J Neuroimmunol* **67**, 21-29.
- [36] Mizwicki MT, Liu G, Fiala M, Magpantay L, Sayre J, Siani A, Mahanian M, Weitzman R, Hayden EY, Rosenthal MJ, Nemere I, Ringman J, Teplow DB (2013) 1alpha,25-dihydroxyvitamin D3 and resolvin D1 retune the balance between amyloid-beta phagocytosis and inflammation in Alzheimer's disease patients. *J Alzheimers Dis* **34**, 155-170.
- [37] Arita M, Ohira T, Sun YP, Elangovan S, Chiang N, Serhan CN (2007) Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. *J Immunol* **178**, 3912-3917.
- [38] Doens D, Fernandez PL (2014) Microglia receptors and their implications in the response to amyloid beta for Alzheimer's disease pathogenesis. *J Neuroinflammation* **11**, 48.
- [39] Fassbender K, Walter S, Kuhl S, Landmann R, Ishii K, Bertsch T, Stalder AK, Muehlhauser F, Liu Y, Ulmer AJ, Rivest S, Lentsch A, Gulbins E, Jucker M, Staufenbiel M, Brechtel K, Walter J, Multhaup G, Penke B, Adachi Y, Hartmann T, Beyreuther K (2004) The LPS receptor (CD14) links innate immunity with Alzheimer's disease. *FASEB J* **18**, 203-205.
- [40] Fiala M, Lin J, Ringman J, Kermani-Arab V, Tsao G, Patel A, Lossinsky AS, Graves MC, Gustavson A, Sayre J, Sofroni E, Suarez T, Chiappelli F, Bernard G (2005) Ineffective phagocytosis of amyloid-beta by macrophages of Alzheimer's disease patients. *J Alzheimers Dis* **7**, 221-232; discussion 255-262.
- [41] Fiala M, Cribbs DH, Rosenthal M, Bernard G (2007) Phagocytosis of amyloid-beta and inflammation: Two faces of innate immunity in Alzheimer's disease. *J Alzheimers Dis* **11**, 457-463.
- [42] Zaghi J, Goldenson B, Inayathullah M, Lossinsky AS, Masoumi A, Avagyan H, Mahanian M, Bernas M, Weinand M, Rosenthal MJ, Espinosa-Jeffrey A, de Vellis J, Teplow DB, Fiala M (2009) Alzheimer disease macrophages shuttle amyloid-beta from neurons to vessels, contributing to amyloid angiopathy. *Acta Neuropathol* **117**, 111-124.
- [43] Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T, Basun H, Faxen-Irving G, Garlind A, Vedin I, Vessby B, Wahlund LO, Palmblad J (2006) Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegaAD study: A randomized double-blind trial. *Arch Neurol* **63**, 1402-1408.
- [44] Samuelsson B (2012) Role of basic science in the development of new medicines: Examples from the eicosanoid field. *J Biol Chem* **287**, 10070-10080.
- [45] Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, Gronert K (2000) Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. *J Exp Med* **192**, 1197-1204.
- [46] Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN (2001) Lipid mediator class switching during acute inflammation: Signals in resolution. *Nat Immunol* **2**, 612-619.
- [47] Serhan CN (2014) Pro-resolving lipid mediators are leads for resolution physiology. *Nature* **510**, 92-101.
- [48] Hong S, Gronert K, Devchand PR, Moussignac RL, Serhan CN (2003) Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. *J Biol Chem* **278**, 14677-14687.
- [49] Marcheselli VL, Hong S, Lukiw WJ, Tian XH, Gronert K, Musto A, Hardy M, Gimenez JM, Chiang N, Serhan CN, Bazan NG (2003) Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. *J Biol Chem* **278**, 43807-43817.
- [50] Mukherjee PK, Marcheselli VL, Serhan CN, Bazan NG (2004) Neuroprotectin D1: A docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. *Proc Natl Acad Sci U S A* **101**, 8491-8496.
- [51] Bazan NG, Molina MF, Gordon WC (2011) Docosahexaenoic Acid signalolipidomics in nutrition: Significance in aging, neuroinflammation, macular degeneration, Alzheimer's, and other neurodegenerative diseases. *Annu Rev Nutr* **31**, 321-351.
- [52] Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN (2001) Lipid mediator class switching during acute inflammation: Signals in resolution. *Nat Immunol* **2**, 612-619.
- [53] Serhan CN, Dalli J, Colas RA, Winkler JW, Chiang N (2015) Protectins and maresins: New pro-resolving families of mediators in acute inflammation and resolution bioactive metabolome. *Biochim Biophys Acta* **1851**, 397-413.
- [54] Serhan CN, Chiang N, Dalli J (2015) The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution. *Semin Immunol*, doi: 10.1016/j.smim.2015.03.004
- [55] Serhan CN, Chiang N, Van Dyke TE (2008) Resolving inflammation: Dual anti-inflammatory and pro-resolution lipid mediators. *Nat Rev Immunol* **8**, 349-361.
- [56] Krishnamoorthy S, Recchiuti A, Chiang N, Yacoubian S, Lee CH, Yang R, Petasis NA, Serhan CN (2010) Resolvin D1 binds human phagocytes with evidence for proresolving receptors. *Proc Natl Acad Sci U S A* **107**, 1660-1665.
- [57] Terrando N, Gomez-Galan M, Yang T, Carlstrom M, Gustavsson D, Harding RE, Lindskog M, Eriksson LI (2013) Aspirin-triggered resolvin D1 prevents surgery-induced cognitive decline. *FASEB J* **27**, 3564-3571.
- [58] Serhan CN, Dalli J, Karamnov S, Choi A, Park CK, Xu ZZ, Ji RR, Zhu M, Petasis NA (2012) Macrophage proresolving mediator maresin 1 stimulates tissue regeneration and controls pain. *FASEB J* **26**, 1755-1765.
- [59] Dalli J, Chiang N, Serhan CN (2014) Identification of 14-series sulfido-conjugated mediators that promote resolution of infection and organ protection. *Proc Natl Acad Sci U S A* **111**, E4753-E4761.
- [60] Colas RA, Shinohara M, Dalli J, Chiang N, Serhan CN (2014) Identification and signature profiles for pro-resolving and inflammatory lipid mediators in human tissue. *Am J Physiol Cell Physiol* **307**, C39-C54.
- [61] Dalli J, Kraft BD, Colas RA, Shinohara M, Fredenburgh LE, Hess DR, Chiang N, Welty-Wolf KE, Choi AM, Piantadosi CA, Serhan CN (2015) Proresolving lipid mediator profiles in baboon pneumonia are regulated by inhaled carbon monoxide. *Am J Respir Cell Mol Biol*, doi: 10.1165/rcmb.2014-0299OC.
- [62] Serhan CN, Dalli J, Karamnov S, Choi A, Park CK, Xu ZZ, Ji RR, Zhu M, Petasis NA (2012) Macrophage proresolving mediator maresin 1 stimulates tissue regeneration and controls pain. *FASEB J* **26**, 1755-1765.
- [63] Gordon S, Mantovani A (2011) Diversity and plasticity of mononuclear phagocytes. *Eur J Immunol* **41**, 2470-2472.
- [64] Gautier EL, Shay T, Miller J, Greter M, Jakubzick C, Ivanov S, Helft J, Chow A, Elpek KG, Gordonov S, Mazloom AR,

- Ma'ayan A, Chua WJ, Hansen TH, Turley SJ, Merad M, Randolph GJ, Immunological Genome C (2012) Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages. *Nat Immunol* **13**, 1118-1128.
- [65] Stables MJ, Shah S, Camon EB, Lovering RC, Newson J, Bystrom J, Farrow S, Gilroy DW (2011) Transcriptomic analyses of murine resolution-phase macrophages. *Blood* **118**, e192-e208.
- [66] Schiff-Zuck S, Gross N, Assi S, Rostoker R, Serhan CN, Ariel A (2011) Saturated-efferocytosis generates pro-resolving CD11b low macrophages: Modulation by resolvins and glucocorticoids. *Eur J Immunol* **41**, 366-379.
- [67] Titos E, Rius B, Gonzalez-Periz A, Lopez-Vicario C, Moran-Salvador E, Martinez-Clemente M, Arroyo V, Claria J (2011) Resolvin D1 and its precursor docosahexaenoic acid promote resolution of adipose tissue inflammation by eliciting macrophage polarization toward an M2-like phenotype. *J Immunol* **187**, 5408-5418.
- [68] Hellmann J, Tang Y, Kosuri M, Bhatnagar A, Spite M (2011) Resolvin D1 decreases adipose tissue macrophage accumulation and improves insulin sensitivity in obese-diabetic mice. *FASEB J* **25**, 2399-2407.
- [69] Dalli J, Zhu M, Vlasenko NA, Deng B, Haeggstrom JZ, Petasis NA, Serhan CN (2013) The novel 13S,14S-epoxy-maresin is converted by human macrophages to maresin 1 (MaR1), inhibits leukotriene A4 hydrolase (LTA4H), and shifts macrophage phenotype. *FASEB J* **27**, 2573-2583.
- [70] Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen PS, Siemers E, Liu-Seifert H, Mohs R, Alzheimer's Disease Cooperative Study Steering Committee, Solanezumab Study Group (2014) Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. *N Engl J Med* **370**, 311-321.
- [71] Lukiw WJ, Cui JG, Marcheselli VL, Bodker M, Botkjaer A, Gotlinger K, Serhan CN, Bazan NG (2005) A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. *J Clin Invest* **115**, 2774-2783.
- [72] Eckenhoff RG, Laudansky KF (2013) Anesthesia, surgery, illness and Alzheimer's disease. *Prog Neuropsychopharmacol Biol Psychiatry* **47**, 162-166.
- [73] Berger M, Burke J, Eckenhoff R, Mathew J (2014) Alzheimer's disease, anesthesia, and surgery: A clinically focused review. *J Cardiothorac Vasc Anesth* **28**, 1609-1623.
- [74] Zhang B, Tian M, Zheng H, Zhen Y, Yue Y, Li T, Li S, Marcantonio ER, Xie Z (2013) Effects of anesthetic isoflurane and desflurane on human cerebrospinal fluid Abeta and tau level. *Anesthesiology* **119**, 52-60.
- [75] Chiang N, Schwab JM, Fredman G, Kasuga K, Gelman S, Serhan CN (2008) Anesthetics impact the resolution of inflammation. *PLoS One* **3**, e1879.
- [76] Mas E, Croft KD, Zahra P, Barden A, Mori TA (2012) Resolvins D1, D2, and other mediators of self-limited resolution of inflammation in human blood following n-3 fatty acid supplementation. *Clin Chem* **58**, 1476-1484.
- [77] Barden A, Mas E, Croft KD, Phillips M, Mori TA (2014) Short-term n-3 fatty acid supplementation but not aspirin increases plasma proresolving mediators of inflammation. *J Lipid Res* **55**, 2401-2407.
- [78] Swardfager W, Lanctot K, Rothenburg L, Wong A, Cappell J, Herrmann N (2010) A meta-analysis of cytokines in Alzheimer's disease. *Biol Psychiatry* **68**, 930-941.
- [79] Fiala M (2015) Curcumin and omega-3 fatty acids enhance NK cell-induced apoptosis of pancreatic cancer cells but curcumin inhibits interferon-gamma production: Benefits of omega-3 with curcumin against cancer. *Molecules* **20**, 3020-3026.
- [80] Barberger-Gateau P, Samieri C, Feart C, Plourde M (2011) Dietary omega 3 polyunsaturated fatty acids and Alzheimer's disease: Interaction with apolipoprotein E genotype. *Curr Alzheimer Res* **8**, 479-491.